🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on communication apps, based on recent findings.

Investigational Treatment Gaining Traction Online

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing effects. Followers are urged to contact these profiles directly for source information, while also receiving promotional offers.

Active Trade on Social Networks

Separately, a robust market exists on messaging services, where groups with numerous of participants share “before and after” photos, injection guides and assertions of rapid British shipping. Vendors promote the drug there before directing buyers to other platforms for transactions.

Understanding The Experimental Drug

Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist individuals lose up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed online as the successor to Ozempic.

Healthcare Experts Express Concerns

Nevertheless, physicians and pharmacists have cautions that the sale of what remains an unapproved drug in the UK is a cause for concern and could result in users administering products of unknown origin.

Several experts said the popularity for the experimental drug could be connected to the increasing cost of approved slimming treatments such as Mounjaro.

Regulatory Status and Enforcement

Selling retatrutide on TikTok or messaging apps is illegal in the UK, as it is an unlicensed medication that must not be marketed or distributed for human use under the Human Medicines Regulations 2012.

Several content creators attempt to circumvent the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and supply can still breach medicines, marketing, and consumer laws, risking fines, legal action or prison.

Service Reaction and Material Removal

Based on the social media company, the platform has taken down violative material and banned related hashtags and query recommendations. The organization said it was dedicated to maintaining the service secure and investing in enhancing enforcement strategies.

Digital Trading Operations

Investigations also discovered groups with up to 9,000 members selling retatrutide using the platform's built-in discovery tool, which operates like a public directory. Entering “retatrutide” immediately displays groups with thousands of members, filled with images of slimming results, positive testimonials and step-by-step instructions for preparing or administering at residence.

Within minutes of entering one group, a vendor posted contact information, where the majority of transactions take place. The vendor provided an guidebook and guaranteed delivery within two days. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one asked about weight, health issues or past usage.

Item Details and Costs

Inside these groups, messages show dark colored parcels with postal service stickers, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled injectors usually sold at 160 pounds for 20 milligrams. When questioned how long a pen should last, vendors give conflicting responses ranging from a few weeks to “depends on your body”.

Platform Moderation and Safety Measures

A representative for Telegram said it actively monitored harmful material on its service including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“People are administering substances they cannot confirm. Although the science behind retatrutide is sound, these digital versions may not include what they claim,” stated Jason Murphy, the head of pharmacy at a pharmacy service.

A medical professional of an online medical service linked the increase in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to social media. But counterfeit treatments are extremely dangerous. You cannot know what’s contained or whether the environment they were produced in was sterile,” she explained.

Her staff has already encountered individuals injured by self-injection from unconfirmed suppliers. “We understand the frustration, but purchasing from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Producer Position

A spokesperson from Eli Lilly stated the substance was in third stage research studies and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a Lilly investigational product not yet authorized … may subject patients to possibly significant health risks”.